Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2012

View Archived Issues

New 5-lipoxygenase inhibitors claimed by Ranbaxy Laboratories

AZD-4694 PET detects Alzheimer's disease pathology in patients

Cancer vaccine shows activity in phase I/II trial

Kampo medicine reduces oxaliplatin-induced peripheral neuropathy in patients with cancer

Novel approach yields first small-molecule ligand for wild-type p53 DNA-binding domain

Panobinostat trial in colorectal cancer yields mixed results

Vanderbilt University patents new indoles

New insulin secretagogues prepared in Japan

Phase II trial investigates GS-7340 as part of a new treatment regimen

Amorcyte kicks off enrollment in phase II AMR-001 study

AC Immune and University of Basel enter research agreement

Sanwa Kagaku Kenkyusho presents novel glucokinase activators

Novel somatostatin receptor ligands reported

FDA approves gel for actinic keratosis

Incyte synthesizes novel PI3K-delta inhibitors

FDA clears updated Vytorin label

Bilastine launched in Brazil

New protease-activated PAR1 receptor antagonists disclosed

FDA expands Keppra indication

Neurocrine Biosciences product gets FDA fast track status

Spectrum Pharmaceuticals enters licensing agreement for Zevalin

CHMP issues opinion on Remicade for ulcerative colitis in children

Phase III afatinib trials begin in head and neck cancer

Targovax secures funding for cancer vaccine research

Initial phase III data show promise for tasimelteon

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...